Novartis trial setback: del-desiran fails late-stage main goal
Novartis said del-desiran, an experimental treatment for myotonic dystrophy type 1, failed to meet the main goal of a late-stage study, marking its third clinical-trial setback in a week.
The setback adds to pressure on the Swiss drugmaker as it looks for new…